Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-Hypertension: Orforglipron in Hypertension with Obesity or Overweight
2024-519000-27-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of orforglipron in hypertension (HTN), Overweight and obesity (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: GZPL Allocation, GZL1 office systolic blood pressure and 1 more. Planned start Jul 2025; status: authorised.
02
Drugs
orforglipron
03
Conditions
hypertension (HTN)Overweightobesity
Beyond the preview
Go deeper on 2024-519000-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519000-27-00.